Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-10-26
DOI
10.3389/fphar.2016.00405
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
- (2016) Yukiko Tabuchi et al. BREAST CANCER RESEARCH AND TREATMENT
- Improved Survival of HER2+Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
- (2016) Keith L. Knutson et al. CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer
- (2016) Kazuhiro Yoshimura et al. EUROPEAN UROLOGY
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
- (2016) Barbara Melosky et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand-Independent EGFR Signaling
- (2015) G. Guo et al. CANCER RESEARCH
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
- (2015) X. Liu et al. CANCER RESEARCH
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
- (2015) H. G. Caruso et al. CANCER RESEARCH
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
- (2015) M. Noguchi et al. CLINICAL CANCER RESEARCH
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
- (2015) Cheng Lin et al. Clinical Lung Cancer
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
- (2015) Yanna Tang et al. Oncotarget
- STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
- (2015) R. M. Srivastava et al. Cancer Immunology Research
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
- (2015) Jianfeng Han et al. Scientific Reports
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Personalized Peptide Vaccine for Treatment of Advanced Cancer
- (2014) Tetsuro Sasada et al. CURRENT MEDICINAL CHEMISTRY
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
- (2014) KAZUYA OFUJI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma
- (2014) J. P. Pandey et al. NEURO-ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
- (2014) Koichi Azuma et al. PLoS One
- EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
- (2013) T Kumai et al. BRITISH JOURNAL OF CANCER
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer
- (2013) Dorte Aa. Olsen et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
- (2013) Teppei Yamada et al. PLoS One
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
- (2011) Patrick J Schuler et al. Journal of Translational Medicine
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients
- (2009) Pedro A. Andrade Filho et al. JOURNAL OF IMMUNOTHERAPY
- The biological properties of cetuximab
- (2008) Bruno Vincenzi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
- (2008) John H. Sampson et al. SEMINARS IN IMMUNOLOGY
- Autoantibodies in lung cancer: possibilities for early detection and subsequent cure
- (2007) C J Chapman et al. THORAX
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now